Utility of the metabolic syndrome and its components in the prediction of incident cardiovascular disease: A prospective cohort study

European Journal of Preventive Cardiology

Volumn 16, Issue 2, 2009, Pages 235-241

  Knuiman, Matthew W ^a   Hung, Joseph ^a   Divitini, Mark L ^a   Davis, Timothy M ^b   Beilby, John P ^c  

^a Sir Charles Gairdner Hospital Unit   (United States)

^b Fremantle Hospital Unit   (United States)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

cardiovascular disease; cohort study; metabolic syndrome

Indexed keywords

ADULT; AGED; ARTICLE; AUSTRALIA; CARDIOVASCULAR DISEASE; FEMALE; HEALTH SURVEY; HUMAN; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE CLASSIFICATION; FOLLOW UP; GLUCOSE BLOOD LEVEL; HAZARD RATIO; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; OBESITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL MODEL; STROKE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; FEMALE; HEALTH STATUS INDICATORS; HUMANS; INCIDENCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; WESTERN AUSTRALIA;

GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

EID: 67449084423     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32832955fc     Document Type: Article

References (26)

1. Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988; 37: 1595–1607.
2. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement: Executive Summary. Circulation 2005; 112: e285–e290.
3. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998; 15: 539–553.
4. Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome – a new worldwide definition. Lancet 2005; 366: 1059–1062.
5. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003; 108: 1541–1545.
6. Kahn R, Buse J, Ferrannini E, Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28: 2289–2304.
7. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716.
8. Stern MP, Williams K, Gonzalez-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27: 2676–2681.
9. The Diabetes Epidemiology Collaborative analysis of diagnostic criteria in Europe (DECODE) study group. Does diagnosis of the metabolic syndrome detect further men at high risk of cardiovascular death beyond those identified by a conventional cardiovascular risk score? The DECODE Study. Eur J Cardiovasc Prev Rehab 2007; 14: 192–199.
10. Dekker JM, Girman C, Rhodes T, Nijpels G, Stehouwer CDA, Bouter LM, et al. Metabolic syndrome and 10-year cardiovascular disease risk in the Hoorn Study. Circulation 2005; 112: 666–673.
11. McNeill AM, Rosamond WD, Girman CJ, Golden SH, Schmidt MI, East HE, et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities Study. Diabetes Care 2005; 28: 385–390.
12. Sundstrom J, Riserus U, Byberg L, Zethelius B, Lithell H, Lind L. Clinical value of the metabolic syndrome for long term prediction of total and cardiovascular mortality: prospective, population based cohort study. BMJ 2006; 332: 878–882.
13. Jeppesen J, Hansen TW, Rasmussen S, Ibsen H, Torp-Pedersen C, Madsbad S. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease: A population-based study. J Am Coll Cardiol 2007; 49: 2112–2119.
14. Ninomiya T, Kubo M, Doi Y, Yonemoto K, Tanizaki Y, Rahman M, et al. Impact of metabolic syndrome on the development of cardiovascular disease in a general Japanese population: The Hisayama Study. Stroke 2007; 38: 2063–2069.
15. Garni AS, Witt BJ, Howard DE, Erwin PJ, Garni LA, Somers VK, et al. Metabolic syndrome and risk of incident cardiovascular events and death: A systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007; 49: 403–414.
16. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005; 28: 1769–1778.
17. Knuiman MW, Jamrozik K, Welborn TA, Bulsara MK, Divitini ML, Whittall DE. Age and secular trends in risk factors for cardiovascular disease in Busselton. Aust J Public Health 1995; 19: 375–382.
18. Hung J, McQuillan BM, Chapman CML, Thompson PL, Beilby JP. Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol 2005; 25: 1268–1273.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting insulin and glucose concentrations in man. Diabetologia 1985; 28: 412–419.
20. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837–1847.
21. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–359.
22. Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Intern Med 2004; 164: 1066–1076.
23. Li W, Ma D, Liu M, Liu H, Feng S, Hao Z, et al. Association between metabolic syndrome and risk of stroke: A meta-analysis of cohort studies. Cerebrovasc Dis 2008; 25: 539–547.
24. Cull CA, Jensen CC, Retnakaran R, Holman RR. Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus. UKPDS 78. Circulation 2007; 116: 2119–2126.
25. Meigs JB, Rutter MK, Sullivan LM, Fox CS, D'Agostino RB Sr, Wilson PWF. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome. Diabetes Care 2007; 30: 1219–1225.
26. Hanley AJ, Wagenknecht LE, D'Agostino RB Jr, Zinman B, Haffner SM. Identification of subjects with insulin resistance and beta-cell dysfunction using alternative definitions of the metabolic syndrome. Diabetes 2003; 52: 2740–2747.